---
title: "Vivani: Solid Funding Runway and Strategic Catalysts Underpin Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280894304.md"
description: "Vivani Medical received a Buy rating from Maxim Group analyst Naz Rahman, who set a price target of $4.00. Rahman cites the company's strong financial position, with no debt and sufficient funding to support operations until mid-2027. He also points to strategic catalysts, including a planned spin-off/IPO of Cortigent and the NPM-139 semaglutide implant program, which targets the obesity market with a convenient dosing schedule, as key factors supporting his positive outlook on the stock."
datetime: "2026-03-29T01:35:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280894304.md)
  - [en](https://longbridge.com/en/news/280894304.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280894304.md)
---

# Vivani: Solid Funding Runway and Strategic Catalysts Underpin Buy Rating

Vivani Medical, the Healthcare sector company, was revisited by a Wall Street analyst on March 27. Analyst Naz Rahman from Maxim Group reiterated a Buy rating on the stock and has a $4.00 price target.

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Naz Rahman has given his Buy rating due to a combination of factors, starting with Vivani’s solid financial footing and visibility on funding. The company ended 2025 with a meaningful cash position, no debt, and additional committed equity capital that, in Rahman’s view, should comfortably support operations into mid-2027 and cover the next human clinical trial, reducing near-term financing risk.

Rahman also highlights strategic and clinical catalysts that could unlock substantial value. The planned Cortigent spin-off/IPO would crystallize the value of Vivani’s majority stake while providing non-dilutive funding, and the NPM-139 semaglutide implant program targets a large obesity market with a more convenient twice-yearly dosing schedule, leveraging an already well-understood drug profile and potentially enabling an efficient regulatory path, all of which underpin his constructive stance on the shares.

### Related Stocks

- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [CRGT.US](https://longbridge.com/en/quote/CRGT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [VANI.US](https://longbridge.com/en/quote/VANI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Jefferies Sticks to Their Buy Rating for Dexcom (DXCM)](https://longbridge.com/en/news/286443716.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)